Ryan Basquez, MD
Hospice and Palliative Medicine · Baton Rouge, LANPI 1417488826
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $241 of the $271 with a category attached, or 88.9%. 9 manufacturers reported payments, led by Johnson & Johnson at 34.1% of the total. Reporting peaked in 2022 at $95 and has fallen 62.3% since, to $36 in 2025.
Across 15 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$92
- Pfizer$42
- Merz North America, Inc.$30
- United Therapeutics Corporation$26
- Kestra Medical Technology Services, Inc.$20
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
- plus $43 from 3 others
What the payments were for
- Food & beverage$24189%
- Gifts$3011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $92 |
| Pfizer | 3 | $42 |
| Merz North America, Inc. | 1 | $30 |
| United Therapeutics Corporation | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Vertex | 1 | $16 |
| Merck | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$271 in reported general payments places this provider in the 70th percentile of 21 hospice and palliative medicine providers in Louisiana.
See all hospice and palliative medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 20 | $1,769 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 50 | $1,588 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $1,141 |
| Oxycodone Hcl | 61 | $1,088 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $582 |
| Gabapentin | 25 | $289 |
| Methadone Hcl | 16 | $266 |
| Mirtazapine | 20 | $214 |
| Ondansetron OdtOndansetron | 12 | $154 |
| Pregabalin | 11 | $108 |
| Clonazepam | 16 | $44 |
| Alprazolam | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Baton Rouge
- Ty HargroderEunice$4K
- Kenneth SmithMetairie$4K
- Farah AliCovington$676
- Michelle BergeronLafayette$585
- Trenice AdamsMetairie$560
- Kathryn JonesNew Orleans$440
- Susan NelsonNew Orleans$237
- Katelyn BriggsNew Orleans$215
- Ricardo FebryMetairie$206
- Amardeep SinghTerrytown$164
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.